MSRA has low concordance with skeletal muscle mass index in mixed cancer patients: A preliminary and feasibility study

Clin Nutr ESPEN. 2022 Dec:52:245-249. doi: 10.1016/j.clnesp.2022.11.002. Epub 2022 Nov 5.

Abstract

Background and aims: Currently, there are no studies evaluating the agreement between the Mini Sarcopenia Risk Assessment (MSRA) questionnaire and skeletal muscle mass index (SMI) in cancer patients. Thus, this study aimed to evaluate the agreement of the MSRA questionnaire with SMI in cancer patients.

Methods: Cross-sectional study with 132 unselected cancer patients. The risk of sarcopenia was determined using the MSRA of 5 and 7 questions. Men and women were divided into subgroups with and without risk of sarcopenia, according to MSRA. SMI was assessed by the muscle mass divided by heigh using the Lee's formula. The ROC curve was used to estimate sensitivity, specificity, and area under the curve between MSRA 5 and 7 versus SMI. The Kappa index was used to assess the agreement between them.

Results: MSRA 5 and 7 showed better sensitivity values in women when compared to men. However, better specificity values were obtained in men when compared to women. Although, there was better agreement between MSRA 5/7 and SMI in women, kappa values indicated low agreement in both sexes (MSRA 5: women: 0.36 vs. men: 0.07 and MSRA 7: women: 0.22 vs. men: - 0.07).

Conclusion: MSRA 5 and 7 questionnaires has low agreement with SMI to identify risk of sarcopenia in unselected cancer patients.

Keywords: Cancer; Muscle mass; Muscle strength; Sarcopenia.

MeSH terms

  • Cross-Sectional Studies
  • Feasibility Studies
  • Female
  • Humans
  • Male
  • Muscle, Skeletal / pathology
  • Neoplasms* / complications
  • Neoplasms* / pathology
  • Risk Assessment
  • Sarcopenia* / complications